Crucial US Advisory Committee to Cast Ballots on Altering Infant Hepatitis B Vaccine Guideline
Following a delay and a remarkably divisive session, a federal vaccine advisory panel was set to cast ballots on Friday on whether to change the enduring advisory that all newborns be vaccinated against hepatitis B.
Fiery Exchange and a Delayed Ballot
The first day of the assembly on Thursday was defined by intense argument over curbing eligibility to the hepatitis B vaccine for babies and a decision to delay the ballot by a day to give members more time to examine the language. The committee, which advises the Centers for Disease Control and Prevention on immunization practices, had put off the vote twice in the past.
“Is there any definitive data of injury of giving this immunization before 30 days? Or is this conjecture?” questioned one adviser.
In reply, another participant stated, “There is limited evidence about the prolonged hazard.”
Present Protocol and Potential Impact
The vaccine is currently recommended for all infants within 24 hours of birth to halt contraction of hepatitis B, which can lead to major damage to the liver. It has been provided to more than a billion persons for in excess of thirty years.
The Georgia assembly provided no fresh data of injuries resulting from the vaccine. Authorities state any modification to the existing hepatitis B vaccination schedule could have major and extensive implications for childhood health in the United States.
Panel Composition and Latest Shifts
The consultative group can only provide advice to the leader of the CDC. The group's roster has undergone changes in recent days, with the declaration that the panel's latest chairman would depart for an agency job and be succeeded by a cardiologist who has been critical of other inoculations.
The board includes several vaccine skeptics who are in agreement with a desire to overhaul – and potentially, in some cases, scrap – long-established immunization guidelines.